Two-fraction HDR Monotherapy for Localized Prostate Cancer

This is a single center single arm prospective pilot study investigating the safety of high dose rate (HDR) brachytherapy as monotherapy delivered in 2 fractions 3 hours apart. HDR monotherapy has been established as safe and effective in this context, however previous studies have delivered 2 fractions on separate days, or at least 6 hours apart. Clinically, this regimen, if shown to be safe and effective in future studies, has the potential to reduce operative resources and logistical stresses on brachytherapy departments.

Trial Details

NCT ID
NCT05665738
Phase
NA
Sponsor
University of California, San Francisco
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • High Dose Rate Monotherapy
Locations (sample)
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Participants must have histologically or cytologically confirmed diagnosis of prostate adenocarcinoma.
  • National Comprehensive Cancer Network favorable intermediate risk stratification, defined as one or more intermediate risk factors such as cT2b - c…
  • Age \>=18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status \<2 (Karnofsky \>60%).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →